MedTrace Logo

Benznidazole Absorption, Metabolism and Excretion Study

NCT03739541 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-11-14

No results posted yet for this study

Summary

This Phase I ADME study will be conducted to evaluate the pharmacokinetics of benznidazole.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

[14C]-Benznidazole

A single dose level of 100 mg; 200 μCi (7.4 MBq)

Sponsors & Collaborators

  • Insud Pharma

    collaborator INDUSTRY

  • Exeltis France

    lead UNKNOWN

Principal Investigators

  • Sunu Valasseri, MBBS, MSc · Covance

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2018-09-02
Completion
2018-09-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739541 on ClinicalTrials.gov